This study aims to investigate the prognostic role of XRCC1 and XRCC3 in non-small cell lung cancer (NSCLC) patients treated with chemotherapy. A total of 256 were consecutively selected between January 2003 to November 2006, and all patients were followed-up until November 2011. The genotyping of XRCC1 Arg194Trp, XRCC1 Arg399Gln and XRCC3 Thr241Met was analyzed by duplex polymerase-chain-reaction method. Individuals carrying XRCC1 399Gln/Gln genotype had a longer survival time, and lowered the risk of death from NSCLC (hazard ratio (HR)=0.32, 95% confidence interval (CI)=0.12 to 0.91). Patients with XRCC1 194Trp/Trp showed a longer survival time, and had a 0.29 fold decreased risk of death than those with Arg/Arg genotype (HR=0.71, 95% CI=0.51 to 1.14). For XRCC3 Thr241Met, the variant genotype Met/Met was non-significantly associated with a decreased risk of death from NSCLC when compared with Thr/Thr genotype, with the HR (95% CI) of 0.68 (0.23 to 1.25). This study conducted in a Chinese population indicated XRCC1Arg399Gln gene has a role in modifying the effect of platinum-based chemotherapy for NSCLC patients.
Key words: X-ray repair cross complementing protein 1, x-ray repair cross complementing protein 3, non-small cell lung cancer (NSCLC), chemotherapy.
Copyright © 2020 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0